Results
Title

Oxaliplatin-induced immune mediated thrombocytopenia.

Authors

Beg, Muhammad S.; Komrokji, Rami S.; Ahmed, Kashif; Safa, Malek M.

Abstract

Oxaliplatin is a third generation platinum compound used in patients with advanced colorectal carcinoma. Recently, the mechanism of a rare drug-induced immune thrombocytopenia in patients receiving oxaliplatin has been described. This complication is caused by oxaliplatin-dependent antibodies directed against platelet surface glycoproteins, and is unrelated to myelosuppression. In this report, we describe two patients who developed thrombocytopenia immediately soon after receiving oxaliplatin. Sensitization presumably had occurred after receiving oxaliplatin during preceding courses of multiagent chemotherapy that included oxaliplatin.

Subjects

THROMBOCYTOPENIA; CANCER patients; BLOOD platelet disorders; IMMUNOGLOBULINS; GLYCOPROTEINS

Publication

Cancer Chemotherapy & Pharmacology, 2008, Vol 62, Issue 5, p925

ISSN

0344-5704

Publication type

Academic Journal

DOI

10.1007/s00280-007-0675-5